In 120 people aged 4–66 with acquired hypothalamic obesity, daily setmelanotide cut BMI by 16.5% vs a 3.3% rise with placebo at 52 weeks (P<0.001) and reduced hunger; serious adverse events occurred in 28% vs 8%.
RCTn = 120
Miller et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity